North America Dry Eye Syndrome Market, By Product Type (Tear stimulators, Artificial Tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Drug Class (Lubricating Agent, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose (Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2030.
North America Dry Eye Syndrome Market Analysis and Size
Dry eye illness affects a large percentage of the North America population (from middle age to elderly age). According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. From 9.3 percent in 2020 to roughly 16.0 percent in 2050, the proportion of the population aged 65 and up is predicted to rise. The elderly population is expected to grow, and this group will need to be accommodated.
Data Bridge Market Research analyzes that the dry eye syndrome market which was USD 2.36 billion in 2022, would rocket up to USD 3.76 billion by 2030, and is expected to undergo a CAGR of 6.00% during the forecast period. This indicates that the market value. “Artificial tears” dominates the product type segment of the dry eye syndrome market owing to the growing demand for artificial tears for dry eye syndrome treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Tear stimulators, Artificial Tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Drug Class (Lubricating Agent, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose (Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Mexico, Canada
|
|
Market Players Covered
|
Eli Lilly and Company (U.S.), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Akorn Operating Company LLC (U.S.), Santen Pharmaceuticals Co. Ltd., (Japan), Novaliq GmbH (Germany), Cardinal Health, Inc. (U.S.), Perrigo Company plc (Ireland), Sun Pharmaceutical Industries Ltd. (India), Cipla Inc. (U.S.), Alembic Pharmaceuticals Limited (India), Senju Pharmaceutical Co. Ltd. (Japan), Horus Pharma (France), ROHTO Pharmaceutical Co.,Ltd. (Japan)
|
|
Market Opportunities
|
|
Market Definition
Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a condition in which the surface of the affected person's eyes lacks lubrication or moisture. It's a common ailment that can strike anyone at any time. Aching and burning sensations, sore eyes, red eyes, weary eyes, itchy eyes, photophobia, and other symptoms of dry eye can occur. Watery eyes can also be a symptom, as the dry surface of the eyes over-stimulates the production of the watery component of tears to compensate for the dryness.
Dry Eye Syndrome Market Dynamics
Drivers
- Increasing screen time
With the proliferation of digital devices and the rise in remote work and online education, people are spending more time in front of screens. This has led to an increase in digital eye strain, a common contributor to dry eye syndrome. As a result, there is a growing demand for products and treatments to alleviate dry eye symptoms.
- Increasing prevalence of dry eyes among people
The rising prevalence of dry eyes among people is a primary driver of the dry eye syndrome market's growth. Thyroid disorders, lupus, Sjogren’s syndrome, diabetes, rheumatoid arthritis, scleroderma, and others are the various diseases contributing to the high prevalence of dry eyes among people.
- Rising environmental factors responsible for dry eye syndrome
Environmental factors, such as air pollution, low humidity, and climate change, can exacerbate dry eye symptoms. The changing climate patterns and urbanization in North America have led to a rise in environmental conditions that contribute to dry eye syndrome, driving the need for treatments and management solutions.
- Advancements in healthcare and technology
Advances in medical technology and research have led to the development of more effective diagnostic tools and treatments for dry eye syndrome. Patients and healthcare professionals in North America are increasingly seeking innovative solutions to manage and treat this condition, which has contributed to market growth.
Opportunities
- Development of innovative treatments
There is an opportunity for pharmaceutical companies to invest in research and development of new and more effective treatments for dry eye syndrome. Novel medications and therapies can help address the unmet needs of patients with severe or chronic dry eye conditions.
- Telemedicine and remote consultations
The adoption of telehealth services has surged, especially during the COVID-19 pandemic. This presents an opportunity for healthcare providers to offer remote consultations for dry eye syndrome patients, providing more convenient access to care and ongoing monitoring of the condition.
Restraints
- Limited treatment efficacy
Dry eye syndrom epite advances in treatment options, some patients may not find relief from existing therapies. This limited efficacy can be a significant restraint on market growth as patients may become disillusioned with available treatments.
- High treatment costs
The cost of prescription medications and medical devices used in the management of dry eye syndrome can be prohibitive for some patients, especially when insurance coverage is limited. High treatment costs can deter individuals from seeking and adhering to treatment.
Challenges
- Variability in disease presentation
Dry eye syndrome is a complex condition with various underlying causes and a wide range of symptoms and severity. This variability makes it challenging to develop universal treatment options that work for all patients. Tailoring treatment to individual needs is important but can be complex.
- Undiagnosed cases
A significant challenge is the large number of undiagnosed dry eye syndrome cases. Many individuals may experience dry eye symptoms but do not seek medical attention or may not be properly diagnosed. This hinders the market's potential for growth as there is a substantial untapped patient population.
This dry eye syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dry eye syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In October 2022, Aldeyra Therapeutics, Inc. completed the phase 3 clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for treating allergic conjunctivitis. The company presented the clinical data from the trial at the American Academy of Optometry 2022 Annual Meeting
- In January 2022, NovaBay Pharmaceuticals launched Avenova lubricating eye drops to treat dry eye symptoms. Source: https://www.mordorintelligence.com/industry-reports/dry-eye-disease-market
North America Dry Eye Syndrome Market Scope
The dry eye syndrome market is segmented on the basis of product type, dosage type, drug class, dose, medication type, container type, packaging type, type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Tear stimulators
- Artificial Tears
- Secretagogue
- Others
Dosage Type
- Liquid
- Semi-solid
- Others
Drug Class
- Lubricating Agent
- Cholinergics
- Anti-Inflammatory
- Anti-Infectives
- Anti-Allergics
- Others
Dose
- Unit dose
- Multi-dose
Medication Type
- Prescription (Rx) Drugs
- Over the Counter (OTC) Drugs
Container Type
- Unit-Dose Vials
- Bottles
- Tubes
Packaging Type
- Plastic
- Aluminium
- Glass
Type
- Brands
- Generics
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Dry Eye Syndrome Market Regional Analysis/Insights
The dry eye syndrome market is analyzed and market size insights and trends are provided by country, product type, dosage type, drug class, dose, medication type, container type, packaging type, type, end-users and distribution channel as referenced above.
The countries covered in the dry eye syndrome market report are U.S., Canada and Mexico in North America.
U.S is expected to dominate in market due rise in epidemic and pandemic events and presence of sophisticated healthcare infrastructure.
U.S is fastest growing country in market due to increasing prevalence of dry eyes in the country.
The country section of the report also provide dry eye syndrome individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The dry eye syndrome market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for dry eye syndrome market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the dry eye syndrome market. The data is available for historic period 2010-2020.
Competitive Landscape and Dry Eye Syndrome Market Share Analysis
The dry eye syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dry eye syndrome market.
Some of the major players operating in the dry eye syndrome market are:
- Eli Lilly and Company (U.S.)
- Novartis AG (Switzerland)
- Johnson & Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Allergan (Ireland)
- Bausch Health Companies Inc. (Canada)
- Akorn Operating Company LLC (U.S.)
- Santen Pharmaceuticals Co. Ltd., (Japan)
- Novaliq GmbH (Germany)
- Cardinal Health, Inc. (U.S.)
- Perrigo Company plc (Ireland)
- Sun Pharmaceutical Industries Ltd. (India)
- Cipla Inc. (U.S.)
- Alembic Pharmaceuticals Limited (India)
- Senju Pharmaceutical Co. Ltd. (Japan)
- Horus Pharma (France)
- ROHTO Pharmaceutical Co.,Ltd. (Japan)
SKU-